BCD-283 is an antibody-drug conjugate consisting of a monoclonal antibody (USAN -brentuximab) targeting the CD30 receptor protein¹ on the surface of immune cells (particularly CD30-positive tumor cells) and monomethylauristatin E (MMAE) toxin², which is released during cleavage of the conjugate.

A monoclonal antibody is a protein engineered by scientists in the laboratory, equivalent to the natural antibodies of the immune system, aimed at binding to a specific target site in the human body³.

BCD-283 is one of BIOCAD’s drug products under clinical development.

The mechanism of action of the innovative drug product is the binding of BCD-283 to the surface of a CD30-positive tumor cell with further penetration of the drug product inside the cell. Inside the cell there is a release of MMAE toxin, which upon binding to tubulin⁴ causes cellular run arrest, leading to apoptosis of CD30-positive tumor cells. BCD-283 is expected to exert antitumor effects on CD30-positive tumor cells.

This website section contains information about an investigational drug for human use.

1. CD30 (also known as TNFRSF8) is a cellular membrane surface receptor protein from the receptor family of tumor necrosis factors.
2. MMAE is the monomethylauristatin E toxin.
3. Weiner L. M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–327.
4. Tubulin is a protein from which microtubules (structures that make up the cytoskeleton of the cell) are built.